The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Open accessAbstract
In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Toll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,041
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (1976) · Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,791
Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,533
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,514
Oncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Takeuchi, O., Hoshino, K., & Akira, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5392 · Cited by 1,048
Intracavitary bacillus Calmette-Grerin in the treatement of superficial bladder tumors
Morales, A. (1976) · The Journal of Urology · Cited by 978
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Tumor-associated macrophages: from basic research to clinical application
Yang, L., & Zhang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0430-2 · Cited by 847
Toll-like receptor 2 controls expansion and function of regulatory T cells
Sutmuller, R. P. M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25439 · Cited by 756
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
McCarthy, E. F. (2006) · Europe PMC (PubMed Central) · Cited by 747
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746
MyD88: a central player in innate immune signaling
Deguine, J., & Barton, G. M. (2014) · F1000Prime Reports · doi:10.12703/p6-97 · Cited by 692
TAMeless traitors: macrophages in cancer progression and metastasis
Aras, S., & Zaidi, M. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.356 · Cited by 609
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9223-6 · Cited by 515
Alarmins: awaiting a clinical response
Chan, J. K., Roth, J., Oppenheim, J. J., Tracey, K. J., Vogl, T., Feldmann, M., Horwood, N., & Nanchahal, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62423 · Cited by 511
Scanga, C. A., Aliberti, J., Jankovic, D., Tilloy, F., Bennouna, S., Denkers, E. Y., Medzhitov, R., & Sher, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.5997 · Cited by 487
Damage-associated molecular patterns in cancer: a double-edged sword
Hernandez, C., Huebener, P., & Schwabe, R. F. (2016) · Oncogene · doi:10.1038/onc.2016.104 · Cited by 480
Toll-like receptor 2 signaling modulates the functions of CD4 + CD25 + regulatory T cells
Liu, H., Komai-Koma, M., Xu, D., & Liew, F. Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601554103 · Cited by 440
Development of TLR9 agonists for cancer therapy
Krieg, A. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31414 · Cited by 429
Coley, W. B. (1910) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591571000301601 · Cited by 423
Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity
Liu, B., Qu, L., & Yan, S. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0260-7 · Cited by 415
Yang, D., Han, Z., & Oppenheim, J. J. (2017) · Immunological Reviews · doi:10.1111/imr.12577 · Cited by 405
Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008982 · Cited by 400 · cited 1×
“It was recently shown that an attenuated strain of Clostridium novyi efficiently decreased tumor size not only in a rat model but also in dogs with spontaneous solid tumors and one sarcoma patient (32).”
BackgroundDhodapkar, M. V., Sznol, M., Zhao, B., Wang, D., Carvajal, R. D., Keohan, M. L., Chuang, E., Sanborn, R. E., Lutzky, J., Powderly, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008068 · Cited by 365
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
Curtin, J. F., Liu, N., Candolfi, M., Xiong, W., Assi, H., Yagiz, K., Edwards, M. R., Michelsen, K. S., Kroeger, K. M., Liu, C., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000010 · Cited by 364
Expression and function of Toll-like receptors in T lymphocytes
Kabelitz, D. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.11.007 · Cited by 361
Masquerader: High Mobility Group Box-1 and Cancer
Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., & Lotze, M. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1953 · Cited by 355
He, W., Liu, Q., Wang, L., Chen, W., Li, N., & Cao, X. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.01.022 · Cited by 340
TLR agonists: our best frenemy in cancer immunotherapy
Kaczanowska, S., Joseph, A. M., & Davila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 339
Toll-Like Receptor Agonists in Cancer Therapy
Adams, S. (2009) · Immunotherapy · doi:10.2217/imt.09.70 · Cited by 310
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304
Molecular Repolarisation of Tumour-Associated Macrophages
Van Dalen, F. J., Van Stevendaal, M. H. M. E., Fennemann, F. L., Verdoes, M., & Ilina, O. (2018) · Molecules · doi:10.3390/molecules24010009 · Cited by 302
Sato-Kaneko, F., Yao, S., Ahmadi, A., Zhang, S. S., Hosoya, T., Kaneda, M. M., Varner, J. A., Pu, M., Messer, K. S., Guiducci, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93397 · Cited by 280
Takizawa, H., Fritsch, K., Kovtonyuk, L. V., Saito, Y., Yakkala, C., Jacobs, K., Ahuja, A. K., Lopes, M., Hausmann, A., Hardt, W.-D., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.06.013 · Cited by 273
Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages
Müller, E., Christopoulos, P. F., Halder, S., Lunde, A., Beraki, K., Speth, M., Øynebråten, I., & Corthay, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01383 · Cited by 239
Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword
Dajon, M., Iribarren, K., & Cremer, I. (2017) · Immunobiology · doi:10.1016/j.imbio.2016.06.009 · Cited by 210
Carpentier, A., Metellus, P., Ursu, R., Zohar, S., Lafitte, F., Barrie, M., Meng, Y., Richard, M., Parizot, C., Laigle-Donadey, F., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop047 · Cited by 206
Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense
Basith, S., Manavalan, B., Yoo, T. H., Kim, S. G., & Choi, S. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0802-7 · Cited by 203
The Effects of TLR Activation on T-Cell Development and Differentiation
Jin, B., Sun, T., Yu, X.-H., Yang, Y.-X., & Yeo, A. E. T. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/836485 · Cited by 201
Immunotherapy for bladder cancer
Green, J., Fuge, O., Allchorne, P., & Vasdev, N. (2015) · Research and Reports in Urology · doi:10.2147/rru.s63447 · Cited by 194
The Role of Toll-Like Receptor in Inflammation and Tumor Immunity
Cen, X., Liu, S., & Cheng, K. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00878 · Cited by 188
Alvarado, A. G., Thiagarajan, P. S., Mulkearns-Hubert, E. E., Silver, D. J., Hale, J. S., Alban, T. J., Turaga, S. M., Jarrar, A., Reizes, O., Longworth, M. S., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2016.12.001 · Cited by 187
Listeria monocytogenes Promotes Tumor Growth via Tumor Cell Toll-Like Receptor 2 Signaling
Huang, B., Zhao, J., Shen, S., Li, H., He, K.-L., Shen, G.-X., Mayer, L., Unkeless, J., Li, D., Yuan, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4067 · Cited by 182
Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications
Diaz-Montero, C. M., Finke, J., & Montero, A. J. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.003 · Cited by 172
Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation
Wang, J. Q., Jeelall, Y. S., Ferguson, L. L., & Horikawa, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00367 · Cited by 169
Nyirenda, M. H., Sanvito, L., Darlington, P. J., O’Brien, K., Zhang, G.-X., Constantinescu, C. S., Bar-Or, A., & Gran, B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003715 · Cited by 160
Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions
Kramer, M. G., Masner, M., Ferreira, F. A., & Hoffman, R. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00016 · Cited by 145
Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help
Garay, R. P., Viens, P., Bauer, J., Normier, G., Bardou, M., Jeannin, J., & Chiavaroli, C. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.018 · Cited by 144
The application of Toll like receptors for cancer therapy
So, E. Y., & Ouchi, T. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.675 · Cited by 144
The contribution of direct TLR signaling to T cell responses
Rahman, A. H., Taylor, D. K., & Turka, L. A. (2009) · Immunologic Research · doi:10.1007/s12026-009-8113-x · Cited by 143
MYD88 L265P Mutation in Lymphoid Malignancies
Yu, X., Li, W., Deng, Q., Li, L., Hsi, E. D., Young, K. H., Zhang, M., & Li, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0215 · Cited by 140
Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma
Sheyhidin, I., Nabi, G., Hasim, A., Zhang, R.-P., Ainiwaer, J., Ma, H., & Wang, H. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i32.3745 · Cited by 133
Application potential of toll-like receptors in cancer immunotherapy: Systematic review
Shi, M., Chen, X., Ye, K., Yao, Y., & Yu, L. (2016) · Medicine · doi:10.1097/md.0000000000003951 · Cited by 123
Targeting Toll-Like Receptors for Cancer Therapy
Braunstein, M. J., Kucharczyk, J. R., & Adams, S. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0589-7 · Cited by 122
Müller, E., Speth, M. T., CHRISTOPOULOS, P. F., Lunde, A., Avdagic, A., Øynebråten, I., & Corthay, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02520 · Cited by 120
Takeda, Y., Kataoka, K., Yamagishi, J., Ogawa, S., Seya, T., & Matsumoto, M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.015 · Cited by 119
The paradoxical effect of bevacizumab in the therapy of malignant gliomas
Thompson, E. M., Frenkel, E. P., & Neuwelt, E. A. (2010) · Neurology · doi:10.1212/wnl.0b013e318204a3af · Cited by 116
Toll-Like Receptors and Prostate Cancer
Zhao, S., Zhang, Y., Zhang, Q., Wang, F., & Zhang, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00352 · Cited by 115
The revival of CpG oligonucleotide-based cancer immunotherapies
Adamus, T., & Kortylewski, M. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73887 · Cited by 104
Brackett, C. M., Kojouharov, B., Veith, J. M., Greene, K. F., Burdelya, L. G., Gollnick, S. O., Abrams, S. I., & Gudkov, A. V. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521359113 · Cited by 103
Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery
Gregg, K. A., Harberts, E. M., Gardner, F. M., Pelletier, M. R., Cayatte, C., Yu, L., McCarthy, M. P., Marshall, J. D., & Ernst, R. K. (2017) · mBio · doi:10.1128/mbio.00492-17 · Cited by 102
Grimmig, T., Matthes, N., Hoeland, K. M., Tripathi, S., Chandraker, A. K., Grimm, M. R., Moench, R., Moll, E.-M., Friess, H., Tsaur, I., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3069 · Cited by 93
Fms-Like Tyrosine Kinase 3 Ligand Recruits Plasmacytoid Dendritic Cells to the Brain
Curtin, J. F., King, G. D., Barcia, C., Liu, C., Hubert, F., Guillonneau, C., Josien, R., Anegón, I., Lowenstein, P. R., & Castro, M. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3566 · Cited by 92
Chochi, K., Ichikura, T., Kinoshita, M., Majima, T., Shinomiya, N., Tsujimoto, H., Kawabata, T., Sugasawa, H., Ono, S., Seki, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4467 · Cited by 89
Beyond MyD88 and TRIF Pathways in Toll-Like Receptor Signaling
Piras, V., & Selvarajoo, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00070 · Cited by 88
Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors
Zhao, B., Vasilakos, J. P., Tross, D., Smirnov, D., & Klinman, D. M. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-12 · Cited by 84
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer
Tuomela, J. M., Sandholm, J. A., Karihtala, P., Ilvesaro, J. M., Vuopala, K. S., Kauppila, J. H., Kauppila, S., Chen, D., Pressey, C. S., Härkönen, P. L., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2181-7 · Cited by 81
LaRosa, D. F., Gelman, A. E., Rahman, A. H., Zhang, J., Turka, L. A., & Walsh, P. T. (2007) · Immunology Letters · doi:10.1016/j.imlet.2006.12.007 · Cited by 79
Toll-Like Receptor-4 Modulation for Cancer Immunotherapy
Awasthi, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00328 · Cited by 78
Microorganisms and Cancer: Quest for a Therapy
Chakrabarty, A. M. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.9.2683-2686.2003 · Cited by 77
TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients
Wang, C., Cao, S., Yan, Y., Ying, Q., Jiang, T., Xu, K., & Wu, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-415 · Cited by 75
TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting
Herrmann, A., Cherryholmes, G. A., Schroeder, A., Phallen, J. A., Alizadeh, D., Xin, H., Wang, T., Lee, H., Lahtz, C., Swiderski, P. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1151 · Cited by 74
Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma
Kauppila, J. H., Takala, H., Selander, K. S., Lehenkari, P. P., Saarnio, J., & Karttunen, T. J. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03991.x · Cited by 72
Weigel, B. J., Cooley, S., DeFor, T. E., Weisdorf, D. J., Panoskaltsis‐Mortari, A., Chen, W., Blazar, B. R., & Miller, J. S. (2012) · American Journal of Hematology · doi:10.1002/ajh.23280 · Cited by 70
Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy
Matsumoto, M., Takeda, Y., Tatematsu, M., & Seya, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01897 · Cited by 69
Dual functional roles of the MyD88 signaling in colorectal cancer development
Wang, L., Yu, K., Zhang, X., & Yu, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.139 · Cited by 66
Roles of toll-like receptors: From inflammation to lung cancer progression (Review)
Gu, J., Liu, Y., Xie, B., Ye, P., Huang, J., & Lü, Z. (2017) · Biomedical Reports · doi:10.3892/br.2017.1034 · Cited by 58
Toll-Like Receptor 9 in Breast Cancer
Sandholm, J. A., & Selander, K. S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00330 · Cited by 44
TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism
New, M. I., Sheikh, S., Bekheet, M., Olzscha, H., Thézénas, M., Care, M. A., Fotheringham, S. A., Tooze, R. M., Kessler, B. M., & Thangue, N. B. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0504 · Cited by 43
Role of TLR4 as a prognostic factor for survival in various cancers: a meta-analysis
Hao, B., Chen, Z., Bi, B., Yu, M., Yao, S., Feng, Y., Yu, Y., Pan, L., Di, D., Luo, G., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24178 · Cited by 41
Deconstructing innate immune signaling in myelodysplastic syndromes
Varney, M. E., Melgar, K., Niederkorn, M., Smith, M. A., Barreyro, L., & Starczynowski, D. T. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.016 · Cited by 40
Chen, X., Cheng, F., Liu, Y., Zhang, L., Song, L., Cai, X., You, T., Fan, X., Wang, D., Gong, A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.016 · Cited by 40
MyD88 in DNA Repair and Cancer Cell Resistance to Genotoxic Drugs
Kfoury, A., Corf, K. L., Sabeh, R. E., Journeaux, A., Badran, B. M., Hussein, N., Lebecque, S., Manié, S. N., Renno, T., & Coste, I. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt120 · Cited by 36
Khan, M. M., Ernst, O., Sun, J., Fraser, I. D. C., Ernst, R. K., Goodlett, D. R., & Nita‐Lazar, A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.032 · Cited by 32
Self-citationTargeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome
Kam, A. Y. F., Piryani, S. O., McCall, C. M., Park, H. S., Rizzieri, D. A., & Doan, P. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3517 · Cited by 26
Mutation and expression analysis of the IDH1, IDH2, DNMT3A, and MYD88 genes in colorectal cancer
Li, W., Xiao, M., Zhang, D., Yu, D., Yang, R., Li, X., & Yao, Y. (2014) · Gene · doi:10.1016/j.gene.2014.05.070 · Cited by 25
Lee, M. K., IV, Xu, S., Fitzpatrick, E. H., Sharma, A., Graves, H. L., & Czerniecki, B. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074698 · Cited by 23
Garcia‐Manero, G., Bravo, G. M., Yang, H., Wei, Y., Alvarado, Y., Dinardo, C. D., Daver, N. G., Konopleva, M. Y., Hearn, K. P., Miller, R. M., et al. (2016) · Blood · doi:10.1182/blood.v128.22.227.227 · Cited by 23
Repressing DNA Repair to Enhance Chemotherapy: Targeting MyD88 in Colon Cancer
Williamson, E. A., & Hromas, R. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt148 · Cited by 7
Editorial: Immunotherapy for Tumor in the Brain: Insights From—and For—Other Tumor Sites
Lampson, L. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00128 · Cited by 7
Cited by
Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Duan, T., Du, Y., Xing, C., Wang, H. Y., & Wang, R.-F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812774 · Cited by 972
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Cervical cancer in low and middle‑income countries (Review)
Hull, R., Mbele, M., Makhafola, T., Hicks, C., Wang, S., Reis, R., Mehrotra, R., Mkhize‑Kwitshana, Z., Kibiki, G., Bates, D., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11754 · Cited by 544
Harnessing innate immune pathways for therapeutic advancement in cancer
Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 255
Choi, Y., Lichterman, J. N., Coughlin, L. A., Poulides, N., Li, W., Del Valle, P., Palmer, S. N., Gan, S., Kim, J., Zhan, X., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abo2003 · Cited by 132
Metadata
- Authors
- Urban-Wojciuk, Z., Khan, M. M., Oyler, B. L., Fåhraeus, R., Marek-Trzonkowska, N., Nita-Lazar, A., Hupp, T. R., & Goodlett, D. R.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-10-22
- Volume
- 10
- Pages
- 2388-2388
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2981784931
- Cited by
- 307
- References
- 99
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.